Compare Five Below Inc (FIVE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs TG Therapeutics Inc — how do they compare? Five Below Inc trades at $233.93 (market cap $12.95B), while TG Therapeutics Inc trades at $50.38 (market cap $7.64B). The key difference: Five Below Inc is the larger of the two by market cap, and Five Below Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| FIVE | TGTX | |
|---|---|---|
Market Cap | $12.95B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $247.71 | $59.06 |
52-Week Low | $134.36 | $26.94 |
Enterprise Value | $13.84B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $235.36, down 3.69% on the day but maintains strong technical momentum with bullish moving averages. The company demonstrates consistent revenue growth, reaching $3.88B in 2025, and has beaten earnings estimates in three consecutive quarters. Analyst sentiment remains overwhelmingly positive with 31 buy ratings and a $256.45 consensus price target, representing 9% upside potential from current levels.
FIVE presents a compelling growth story with expanding store footprint and product innovation driving sales. Key risks include consumer spending sensitivity and competitive retail pressures. The stock's premium valuation (P/E 29.53) requires continued execution, but strong institutional interest and positive earnings momentum support the bullish case for long-term investors.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
